Francis Paul Worden

 Francis P. Worden
Nancy Wigginton
Oncology Research Professor of Thyroid Cancer
Clinical Professor of Internal Medicine
Medical School
Available to mentor
Francis Paul Worden
Francis P. Worden
Clinical Professor
  • Center Memberships
  • Recent Publications

  • Manage Your Profile

    • Center Memberships
    • Center Member
      Rogel Cancer Center

    Recent Publications

     See All Publications
    • Journal Article
      Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancer.
      Bandaru R, Fu H, Zheng H, Liang J, Wang L, Gulati S, Hinrichs BH, Teng M, Zhang B, Kocherginsky M, Lin D-C, Hildeman DA, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Gillison ML, El-Gamal D, Wise Draper T, Liu Y. J Clin Invest, 2026 May 19; DOI:10.1172/JCI196284
      PMID: 42154530
    • Journal Article
      Validation of MyHPVscore: a high-performance HPV ctDNA lab developed test
      Mierzwa M, Brenner C. Journal of Molecular Diagnostics, 2026 Apr 30;
    • Journal Article
      BTCRC HN17-111: A Phase 2 Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Treatment of Advanced-Stage Androgen Receptor (AR)-Positive Salivary Gland Carcinoma
      Bruce JY, Fujioka N, Worden F, Mehra R, Laux D, Chae YK, Sulahadeen A, Pease D, Cao Q, Kimple R, Garcia A, Patel MR. International Journal of Radiation Oncology • Biology • Physics, 2026 Apr 18; 125 (1): e23 DOI:10.1016/j.ijrobp.2026.02.046
    • Journal Article
      Systemic Treatment of Thyroid Cancer: ASCO Guideline.
      Saba NF, Ismaila N, Adkins D, Agrawal N, Akhave N, Blomain ES, Cabanillas ME, Chen A, Galloway TJ, Harada G, Li D, Noureldine SI, Scharpf J, Sun LL, Tang M, Wirth L, Worden F, Zandberg DP, Beadle BM. J Clin Oncol, 2026 Apr 1; JCO2600235 DOI:10.1200/JCO-26-00235
      PMID: 41921121
    • Preprint
      Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective Study.
      Bandaru R, Fu H, Zheng H, Liang J, Wang L, Gulati S, Hinrichs BH, Teng M, Zhang B, Kocherginsky M, Lin D, Hildeman DA, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Gillison M, El-Gamal D, Wise-Draper T, Liu Y. 2026 Mar 30; DOI:10.64898/2026.03.24.26348354
      PMID: 41959799
    • Journal Article
      MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.
      Pearson AT, Muzaffar J, Kirtane K, Bellile E, Suresh K, Rosenberg AJ, Worden F, Chung CH, Vokes E, Brenner JC, Bhangale A, McHugh J, Warner K, Nor F, Nor JE, Innes K, Zhai Y, Fu T, Swiecicki PL. Nat Commun, 2026 Mar 19; DOI:10.1038/s41467-026-70653-3
      PMID: 41857036
    • Journal Article
      CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective, non-interventional study of the safety and effectiveness of cemiplimab in immunocompromised/immunosuppressed patients with advanced cutaneous squamous cell carcinoma at 2 years’ follow-up
      Park SJ, Rabinowits G, Kelley MJ, Ruiz ES, Worden F, Zhu C, McIntyre DAG, Quek RGW, Wang J, Tumaneng K, Nia S, Pouliot JF. Skin Journal of Cutaneous Medicine, 2026 Mar 1; 10 (2): s756 DOI:10.25251/hex0h755
    • Additional Scholarship
      Data from FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
      Mierzwa M, Rosen B, Suresh K, Dinesh A, Regan S, Brummel C, Wong K, Casper K, Prince M, Malloy K, Shuman A, Chinn S, Cao Y, Aryal M, Heft-Neal M, Stucken C, Buchakjian M, Forner D, Yalamanchi P, Swiecicki P, Lawrence TS, Akhdar R, Tewari M, Bhambhani C, Walline H, Brenner JC, Shah J, Worden F. 2026 Feb 17; DOI:10.1158/1078-0432.c.8313715